Drug Name: | Aminoglutethimide (125-84-8) |
---|---|
PubChem ID: | 2145 |
SMILES: | CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N |
InchiKey: | ROBVIMPUHSLWNV-UHFFFAOYSA-N |
Therapeutic Category: | Antineoplastic Agents, Aromatase Inhibitors, Enzyme Inhibitors, Estrogen Antagonists, Hormone Antagonists, Hormones |
Molecular Weight (dalton) | : | 232.283 |
LogP | : | 1.3532 |
Ring Count | : | 1 |
Hydrogen Bond Acceptor Count | : | 3 |
Hydrogen Bond Donor Count | : | 2 |
Total Polar Surface Area | : | 72.19 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Cardiovascular Disease | Adenylate kinase (P00568) | Total suppression of aromatase by Cytadren may have adverse effects of cardiovascular disease [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
Osteoporosis | Adenylate kinase (P00568) | Total suppression of aromatase by Cytadren may have adverse effects of increased osteoporosis. [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
Urogenital Atrophy | Adenylate kinase (P00568) | Total suppression of aromatase by Cytadren may have adverse effects of urogenital atrophy [ ADR Type 1 ] | Aromatase inhibitors as potential cancer chemopreventives |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category